Harrow (HROW) Current Deferred Tax Assets (2013 - 2014)
Harrow's (HROW) quarterly Current Deferred Tax Assets came in at $30000.0 in Q4 2014, down 25.0% year-on-year from $40000.0 in Q4 2013, and down 25.0% quarter-over-quarter from $40000.0 in Q4 2013.
Harrow (HROW) Current Deferred Tax Assets (2013 - 2014) Analysis & Trends
Harrow's Current Deferred Tax Assets history runs 2 years deep, the most recent figure standing at $30000.0 for Q4 2014.
- On a quarterly basis, Current Deferred Tax Assets fell 25.0% year-over-year to $30000.0 in Q4 2014; TTM through Dec 2014 was $30000.0, a 25.0% decrease from a year earlier, with the FY2014 full-year figure at $30000.0, down 25.0% from the prior year.
- Current Deferred Tax Assets retreated to $30000.0 in Q4 2014 per HROW's latest filing, from $40000.0 in the prior quarter.
- Across five years, Current Deferred Tax Assets topped out at $40000.0 in Q4 2013 and bottomed at $30000.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 30,000.00 |
| Dec 31, 2014 | 30,000.00 |
| Dec 31, 2013 | 40,000.00 |
| Dec 31, 2013 | 40,000.00 |